Mirror Biologics
Immunomodulatory Vaccines and Immunotherapy Treatments
Company Overview
Snapshot
Founded in May 2004 by Dr. Michael Har-Noy, Mirror Biologics operates with 1–10 employees. The company has raised $42.5 million across three funding rounds. In July 2021, Mirror Biologics announced the initiation of its AlloStim® Phase IIB Clinical Trial (STIMVAX) for patients with metastatic colorectal cancer.
Business overview
Mirror Biologics is an international biopharmaceutical company focused on developing next-generation immunotherapy products. The company's core technology involves living immune cells, specifically a patented immune cell called AlloStim®, which possesses immunomodulatory properties. This technology is designed to educate and modify a patient’s immune system to target and destroy cancers and infectious organisms, as well as to reprogram immune systems weakened by age or chronic infection. Mirror Biologics also develops immunomodulatory vaccines based on its Mirror Effect® technology platform, aiming to re-program immune responses in diseased or elderly patients. The company operates in the Health Tech & Life Sciences sector, with a focus on pharmaceuticals, biotechnology, and oncology, serving markets in the United States, Canada, Malaysia, and Thailand.
Strategic signal
In June 2020, Mirror Biologics and Immunovative Therapies announced US FDA clearance for a universal anti-viral vaccine Phase I/II clinical trial for healthy elderly adults. This development signals the company's strategic expansion into broader infectious disease prevention beyond oncology, leveraging its immunomodulatory platform to address significant public health challenges like viral infections, and potentially opening new market opportunities and partnerships.
Log in to access full profile ›Company Intelligence Q&A
- What is Mirror Biologics' primary focus?
- Mirror Biologics specializes in the development and manufacturing of next-generation immunotherapy products, utilizing living immune cells to treat and prevent diseases like cancer and infectious organisms.
- When did Mirror Biologics initiate its AlloStim® Phase IIB Clinical Trial?
- In July 2021, Mirror Biologics announced the initiation of its AlloStim® Phase IIB Clinical Trial (STIMVAX) for patients with metastatic colorectal cancer.
- What significant regulatory milestone did Mirror Biologics achieve in 2020?
- In June 2020, Mirror Biologics and Immunovative Therapies announced US FDA clearance for a universal anti-viral vaccine Phase I/II clinical trial for healthy elderly adults.
- What is the Mirror Effect® technology platform?
- The Mirror Effect® technology platform is Mirror Biologics' novel approach for immunomodulatory vaccine development, designed to imprint a re-programmed immune response over an existing failed immune response in diseased or elderly patients.
- Which company's assets did Mirror Biologics acquire?
- Mirror Biologics acquired all the assets of Immunovative Therapies.